MediPharm Labs Corp.
MEDIFOTCHealthcare● Active
$0.05
$-0.00(-6.64%)
Market Cap$22184026
P/E Ratio—
52W High$0.076
52W Low$0.041
MediPharm Labs Corp. (MEDIF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEDIF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.00
Est. -$0.00 · +41.4%
Revenue
$0.01B
Est. $0.01B · +3.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
MEDIF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.00 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.00 | -$0.00 | +41.4% | $0.01B | $0.01B | +3.1% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.00 | -$0.00 | -100.6% | $0.01B | $0.01B | +18.9% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.00 | -$0.00 | -69.8% | $0.01B | $0.01B | -7.9% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.00 | -$0.01 | -505.4% | $0.01B | $0.01B | +7.2% |
| — Q2 FY2025 | May 14, 2025 | — | -$0.00 | — | $0.01B | — | — |
| — Q1 FY2025 | Mar 27, 2025 | — | -$0.00 | — | $0.01B | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.00 | — | $0.01B | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
+41.4%
Revenue
$0.01B
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
-100.6%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
-69.8%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-505.4%
Revenue
$0.01B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Mar 27, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2025 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2024 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2024 | $-0.00 | $-0.00 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +41.4% | $0.06 | $0.06 | -2.29% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -100.6% | $0.05 | $0.05 | -1.84% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -69.8% | $0.05 | $0.05 | -5.76% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -505.4% | $0.06 | $0.06 | -4.82% |
| — Q2 FY2025 | May 14, 2025 | — | $0.07 | $0.08 | +7.71% |
| — Q1 FY2025 | Mar 27, 2025 | — | $0.07 | $0.07 | -2.09% |
| — Q4 FY2024 | Nov 14, 2024 | — | $0.05 | $0.05 | -1.70% |
| — Q3 FY2024 | Aug 14, 2024 | — | $0.05 | $0.05 | -5.66% |
Q2 FY2026-2.29%
Report Date
May 12, 2026
EPS Beat/Miss
+41.4%
Price Before
$0.06
Price After
$0.06
Q1 FY2026-1.84%
Report Date
Mar 30, 2026
EPS Beat/Miss
-100.6%
Price Before
$0.05
Price After
$0.05
Q4 FY2025-5.76%
Report Date
Nov 13, 2025
EPS Beat/Miss
-69.8%
Price Before
$0.05
Price After
$0.05
Q3 FY2025-4.82%
Report Date
Aug 14, 2025
EPS Beat/Miss
-505.4%
Price Before
$0.06
Price After
$0.06
Q2 FY2025+7.71%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.08
Q1 FY2025-2.09%
Report Date
Mar 27, 2025
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.07
Q4 FY2024-1.70%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q3 FY2024-5.66%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Avg Beat Reaction-2.29%
Avg Miss Reaction-4.14%
Beat Rate1 / 8 quarters
Largest Move+7.71% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEDIF ends December
MediPharm Labs Corp. (MEDIF) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.00 — beating the analyst consensus of $-0.00 by +41.4%. The next MEDIF earnings date is expected around September 1, 2026.
Each quarter, investors track MEDIF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEDIF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEDIF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEDIF earnings · 5 questionsMediPharm Labs Corp.'s next earnings report is expected around September 1, 2026. MEDIF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEDIF historically reports after market close (AMC).
MEDIF earnings datewhen is MEDIF earningsMEDIF next earnings datewhen does MEDIF report earningsMEDIF earnings calendar
▸ Source: FMP · MediPharm Labs Corp. SEC filings · US GAAP · MediPharm Labs Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026